Celecoxib Through L1CAM To Down-regulation Stat3/NF-kB Expression To Suppress The Proliferation And Metastasis In Panc-1 And Bxpc-3 Cells

Purpose: To provide a theoretical basis for seeking more effective clinical drug target research celecoxib inhibits Panc-1 and Bxpc-3pancreatic cancer cell proliferation and metastasis mechanisms, and explore current resistance mechanisms of pancreatic cancer chemotherapy drugs, point and further improve the comprehensive diagnosis and treatment of pancreatic cancer treatment.Methods: Firstly, compare pancreatic tissue and adjacent tissue’s L1 CAM expression level by immunohistochemistry. Then give celecoxib(0,20, 60, 100 μmol / L)on Panc-1 and Bxpc-3 pancreatic cancer cells.Observe two kinds of pancreatic cancer cell protein expression level of L1 CAM stat3, p-stat3, NF-κB, p-NF-κB by western-blot.MTT experiments analysis two pancreatic cancer cells growth inhibition rate in 24 h, 48 h and72h. Scratches experiments observe two pancreatic cancer cells growth and invasion situation in 0h, 6h, 24 h after dealing with silence L1 CAM and L1 CAM overexpression.Immunofluorescence assay measures Panc-1 and Bxpc-3 pancreatic cancer cells intranuclear p-stat3, p-NF-κB level by overexpression L1 CAM treatment of two kinds of pancreatic cancer cells.Results: 1. L1 CAM expression in pancreatic tissue is stronger than adjacent tissue. 2. Celecoxib can reduce the L1CAM、 Panc-1、stat3、p-stat3、NF-κB and p-NF-κB protein expression level in Panc-1 and Bxpc-3 pancreatic cancer cells and have concentration-dependent trend. 3.MTT experiments confirm that celecoxib can inhibit the growth of Panc-1and Bxpc-3 pancreatic cancer cell lines and cell inhibition rate increase along with drug concentration. 4. Scratch experiments prove L1 CAM can increase the capacity of growth and invasion in two kinds of pancreatic cancer cells. 5. Immunofluorescence confirms stat3 / NF-κB signaling pathway can be activated after Panc-1 and Bxpc-3 pancreatic cancer cell lines treated by L1 CAM overexpression.Conclusions: Celecoxib can inhibit Stat3 / NF-κB signaling pathway by decline the expression of L1 CAM. Thereby reduce pancreatic cancer proliferation and metastasis capacity.